TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Express News | Corrected-TherapeuticsMD Inc: Qtrly Shr (Not 'eps') Loss From Cont Ops $0.09
TherapeuticsMD | 10-Q: Q2 2024 Earnings Report
Express News | TherapeuticsMD Q2 EPS $(0.09) Up From $(0.24) YoY, Sales $234.00K Down From $437.00K YoY
Express News | TherapeuticsMD Inc: Qtrly EPS Loss From Cont Ops $0.09
Express News | TherapeuticsMD Inc: Continues to Evaluate a Variety of Strategic Alternatives
TherapeuticsMD 2Q License Rev $234,000
TherapeuticsMD 2Q Loss Cont Ops 9c/Shr
Express News | TherapeuticsMD Q2 Operating Expenses USD 2.7 Million
Express News | TherapeuticsMD Announces Second Quarter 2024 Financial Results
U.S. Menopause Market Trends Analysis Report 2024-2030 Featuring Pfizer, Novo Nordisk, TherapeuticsMD, Bayer, AbbVie, Pure Encapsulations, and PADAGIS
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
TherapeuticsMD | 10-Q: Q1 2024 Earnings Report
Express News | TherapeuticsMD Q1 EPS $(0.07) Up From $(0.24) YoY
Express News | TherapeuticsMD Inc - Continues to Evaluate a Variety of Strategic Alternatives
TherapeuticsMD 1Q Cont Ops Loss/Shr 7c >TXMD
Express News | TherapeuticsMD Q1 Operating Expenses USD 1.5 Million
Express News | TherapeuticsMD Announces First Quarter 2024 Financial Results
TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD
TherapeuticsMD 2023 Cont Ops Loss/Shr 74c >TXMD